Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) CTO John Rondoni sold 58 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $215.00, for a total value of $12,470.00. Following the completion of the sale, the chief technology officer now directly owns 11,322 shares of the company's stock, valued at approximately $2,434,230. This represents a 0.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.
Inspire Medical Systems Stock Performance
Shares of NYSE:INSP traded down $10.86 during trading on Friday, reaching $203.03. The stock had a trading volume of 794,745 shares, compared to its average volume of 615,158. The business has a fifty day moving average price of $191.71 and a 200-day moving average price of $183.39. The stock has a market cap of $6.08 billion, a PE ratio of 189.75 and a beta of 1.32. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40.
Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.54. The firm had revenue of $203.20 million for the quarter, compared to analyst estimates of $197.59 million. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. The business's revenue was up 32.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.29) earnings per share. Sell-side analysts expect that Inspire Medical Systems, Inc. will post 1.33 earnings per share for the current year.
Wall Street Analyst Weigh In
INSP has been the subject of several research analyst reports. Truist Financial restated a "buy" rating and issued a $240.00 price objective (up from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Robert W. Baird raised their price objective on Inspire Medical Systems from $240.00 to $252.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Wells Fargo & Company raised their price objective on Inspire Medical Systems from $187.00 to $198.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. Royal Bank of Canada reiterated an "outperform" rating and set a $260.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Finally, Piper Sandler reiterated an "overweight" rating and set a $260.00 price target (up from $255.00) on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $233.58.
Read Our Latest Stock Report on INSP
Hedge Funds Weigh In On Inspire Medical Systems
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank boosted its stake in Inspire Medical Systems by 4.1% during the second quarter. Amalgamated Bank now owns 2,005 shares of the company's stock worth $268,000 after buying an additional 79 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Inspire Medical Systems by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 7,879 shares of the company's stock worth $1,461,000 after buying an additional 79 shares during the last quarter. Signaturefd LLC boosted its stake in Inspire Medical Systems by 45.9% during the third quarter. Signaturefd LLC now owns 270 shares of the company's stock worth $57,000 after buying an additional 85 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Inspire Medical Systems by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,193 shares of the company's stock worth $2,836,000 after buying an additional 92 shares during the last quarter. Finally, Quarry LP boosted its stake in Inspire Medical Systems by 30.9% during the third quarter. Quarry LP now owns 449 shares of the company's stock worth $95,000 after buying an additional 106 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.
Inspire Medical Systems Company Profile
(
Get Free Report)
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
See Also
Before you consider Inspire Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.
While Inspire Medical Systems currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
